Background
==========

Hypereosinophilia is a feature of a variety of uncommon hematologic disorders like hyperseosinophilic syndrome (HES), systemic mastocytosis (SM) and chronic eosinophilic leukemia (CEL). Approximately 4% of patients with HES or SM have interstitial deletion of chromosome 4q12 leading to juxtaposition of *FIP1L1* and *PDGFRA*\[[@B1]\]. The fusion product is exquisitely sensitive to therapy with imatinib mesylate, and hence its identification has important therapeutic ramifications particularly in hematologic disorders presenting with hypereosinophilia \[[@B2]-[@B5]\]. We herein present the case of a patient in whom *FIP1L1-PDGFRA* was discovered at the time of evolution from chronic myelomonocytic leukemia (CMML) to refractory acute myeloid leukemia and how therapy with imatinib resulted in durable complete remission.

Case presentation
=================

A 64-year-old Caucasian man presented to our institution with a 6-month history of progressive leukocytosis. Per the patient's outside medical records, a bone marrow biopsy at initial presentation had shown a 100% cellular marrow with marked myeloid hyperplasia. Conventional cytogenetics demonstrated a diploid male karyotype. Fluorescence in situ hybridization studies (FISH) were negative for myelodysplasia-associated abnormalities. Molecular studies were negative for *BCR-ABL* rearrangement, and *JAK2*^*V617F*^ and *MPL*^*W515L*^ mutations. Based on these features, he was diagnosed with myelodysplastic/myeloproliferative neoplasm, unclassifiable, and was started on hydroxyurea, 1.5 grams daily. At presentation to our institution, his white blood cell (WBC) count was 44.6 ×10^9^/L with 76% neutrophils, 6% metamyelocytes, 10% monocytes, 6% lymphocytes, 1% eosinophils and 1% blasts, with absolute monocytosis (4.46 × 10^9^/L) and eosinophilia (0.45 × 10^9^/L). He was anemic (hemoglobin 9.0 g/dL) and mildly thrombocytopenic (platelet count 119 × 10^9^/L). He did not have splenomegaly on physical examination. Bone marrow evaluation performed at presentation to our institution revealed a 100% cellular bone marrow with myeloid hyperplasia. Megakaryocytes were decreased in number and included rare dysplastic forms. Wright-Giemsa stained smears prepared from the bone marrow aspirate were remarkable for increased myeloid cells and trilineage dysplasia; a 500-cell differential count showed mildly increased monocytes (6%) and myeloid blasts (7%). The constellation of findings was diagnostic of chronic myelomonocytic leukemia (CMML-1). Conventional cytogenetics showed trisomy 8 in two of twenty analyzed metaphases; this was confirmed by fluorescence in situ hybridization (FISH) using an alpha-satellite (D8Z2) CEP8 probe (positive in 4% of the cells studied). Reverse transcriptase polymerase chain reaction (RT-PCR) performed on the bone marrow aspirate was negative for *BCR-ABL* fusion. Targeted next-generation sequencing mutation analysis was negative for 53 "hotspot" mutations analyzed as described previously \[[@B6]\].

The patient was enrolled on the SGI-110 clinical trial, a phase 1--2 dose escalation, multicenter study of SGI-110, a DNA hypomethylating agent, in subjects with intermediate or high-risk myelodysplastic syndromes (MDS) or AML. He received two courses of SGI-110, after which he experienced rapidly progressive leukocytosis with a peak WBC count of 126 × 10^9^/L and new onset of peripheral eosinophilia (11%). Bone marrow evaluation performed at this time demonstrated nearly 100% cellularity with myeloid hyperplasia; in contrast to the previous biopsy, prominent eosinophilia and moderate myelofibrosis were noted in this sample (Figure [1](#F1){ref-type="fig"}a-b). Wright-Giemsa stained smears showed increased granulocytes with left-shifted maturation and prominent eosinophilia (16%) in a background of trilineage dysplasia. There was no significant increase in bone marrow monocytes (5%). Myeloid blasts comprised 12% of total nucleated cells. The unexpected and abrupt presence of prominent eosinophilia in the peripheral blood and bone marrow at this point in time prompted us to evaluate for *PDGFRA* rearrangement. FISH analysis performed using a LSI-4q12 tricolor rearrangement probe that hybridizes to the chromosome 4q12 region containing the *FIP1L1*, *CHIC2* and *PDGFRA* genes revealed deletion of the *CHIC2* gene in 86.5% of the cells analyzed indicating the presence of the *FIP1L1-PDGFRA* rearrangement. The *FIP1L1-PDGFRA* fusion transcript was further confirmed by RT-PCR. Low-level trisomy 8 was also detected by FISH in this sample. Based on these findings a diagnosis of myelodysplastic/myeloproliferative neoplasm with eosinophilia and *PDGFRA* rearrangement was rendered. A follow-up bone marrow biopsy after one month showed acute myeloid leukemia with 26% blasts. In addition to persistent low-level trisomy 8, conventional cytogenetics and FISH demonstrated a new clone with *TP53* gene deletion. FISH was positive for deletion of the *CHIC2* gene, *TP53* deletion and trisomy 8 in 90%, 10% and 9% of the analyzed cells, respectively.

![**Bone marrow core biopsy at the time of initial*FIP1L1- PDGFRA*rearrangement discovery.** The bone marrow is hypercellular (100%), with prominent eosinophilia and myeloid hyperplasia, mild increase in immature cells, and features of myelofibrosis manifesting primarily as cellular streaming. (**a**: 10× objective; **b**: 20× objective; hematoxylin and eosin stain).](1756-8722-7-26-1){#F1}

The patient was then started on imatinib mesylate 400 mg daily along with a short course of idarubucin and subcutaneous cytarabine for cytoreduction. He achieved complete hematologic and morphologic remission and went on to receive a matched unrelated allogeneic stem cell transplant (SCT). To date, the patient remains in complete hematologic, morphologic and molecular remission with successful engraftment as demonstrated by chimerism studies. The sequence of events is provided in Table [1](#T1){ref-type="table"}.

###### 

Sequence of clinical events

  **Event sequence**     **WBC (×10**^**9**^**)**   **Eosinophils in PB (%, AEC)**   **Eosinophils in BM (%)**   **Blasts in BM (%)**   **Diagnosis**                                                                               **Intervention**                          **Disease status**
  ---------------------- -------------------------- -------------------------------- --------------------------- ---------------------- ------------------------------------------------------------------------------------------- ----------------------------------------- --------------------
  Initial presentation   44.6                       1, 0.45                          1                           7                      CMML-1                                                                                      SGI-110                                   Refractory
  After 2 months         65.1                       9, 5.8                           5                           4                      CMML-1                                                                                      SGI-110                                   Progression
  After 1 month          126                        11, 13.8                         16                          12                     Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and *PDGFRA* rearrangement   Fludarabine + Cytarabine                  Progression
  After 1 month          6.4                        1, 0.06                          1                           26                     AML with *PDGFRA* rearrangement                                                             Imatinib (with Idarubicin + Cutarabine)   Remission

WBC: white blood cells, PB: peripheral blood, AEC: absolute eosinophil count, BM: bone marrow, CMML: chronic myelomonocytic leukemia, AML: acute myeloid leukemia.

Discussion
==========

The PDGFRA and PDGFRB proteins are members of the class III receptor kinase family that also includes c-KIT, and FLT3 \[[@B7]\]. *PDGFRA* is located on chromosome 4q12 \[[@B8]\]. A small interstitial deletion of 4q12 leads to juxtaposition of *FIP1L1* and *PDGFRA* resulting in a gain of function fusion protein with signal independent kinase activity and therefore increased cell proliferation and survival \[[@B9]\]. This interstitial deletion is generally cryptic and not detectable using standard cytogenetic banding techniques.

*FIP1L1- PDGFRA* rearrangements are often associated with chronic eosinophilic leukemia and hypereosinophilic syndromes \[[@B9],[@B10]\] as well as systemic mastocytosis \[[@B11]\]. Pardanani *et al.* reported a prevalence of approximately 4% for *FIP1L1- PDGFRA* fusion gene in a large series of patients with suspected or established HES or systemic mastocysosis \[[@B1]\]. We recently described a case of chronic neutrophilic leukemia associated with *FIP1L1- PDGFRA* rearrangement \[[@B4]\]. The basis for the apparent lineage predilection of *FIP1L1- PDGFRA* for eosinophils is not well understood. The hypothesis is that it is present in all myeloid lineages, but that eosinophils are particularly sensitive to the *FIP1L1- PDGFRA* proliferative signal \[[@B12]\]. In contrast to rearrangements involving *PDGFRB,* the *FIP1L1- PDGFRA* rearrangement is exceedingly rare in the setting of chronic myelomonocytic leukemia \[[@B13]-[@B16]\]. To our knowledge, only one other case has been reported in the literature by Zota *et al*. \[[@B17]\] In contrast to our patient, the patient reported by Zota *et al.* did not evolve in to acute myeloid leukemia, albeit the acquisition of *FIP1L1- PDGFRA* fusion was considered a feature of disease evolution. Initiation of imatinib resolved eosinophilia but did not effectively improve other counts, and the patient subsequently progressed to CMML-2 and developed extramedullary disease in abdominal lymph nodes; she succumbed in 10 months. A case series from Germany described five patients with *FIP1L1- PDGFRA* who presented with AML and eosinophilia, but no history of antecedent myeloid malignancy was reported for any of the patients \[[@B18]\]. A summary of case reports describing *PDGFRA* rearrangements arising in patients with myeloid neoplasms commonly not associated with such rearrangements is provided in Table [2](#T2){ref-type="table"}. All patients received imatinib therapy and achieved at least a hematologic response. One patient got sorafenib and another got dasatinib after acquiring resistance to imatinib. Two of eight patients maintained molecular response, while two maintained hematologic response at last reported follow up. Notably, clonal acquisition of *FIP1L1-PDGFRA* has not been reported in the setting of acute myeloid leukemia evolving from CMML.

###### 

***PDGFRA*rearrangement in unusual adult myeloid neoplasms**

  **Author/journal**                                             **Disease**                                                                                     **Treatment**                                                                                                  **Outcome**
  -------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Tang et al., Acta Haematol 2012;128:83--87                     Myeloproliferative neoplasm with eosinophilia                                                   Imatinib -- started at 400 mg daily and maintained at 100 mg daily                                             Complete hematologic and molecular remission at 12 months
  Papanikolaou et al., Ann Hematol. 2012 May;91(5):785-7         Chronic eosinophilic leukemia with lytic bone lesions                                           Imatinib 200 mg daily; on progression, nilotinib 400 mg BID                                                    Progressed to erythroblastoid blast crisis after 2 years on TKI
  Sorour et al., Br J Haematol. 2009 Jul;146(2):225-7            Acute myeloid leukemia with eosinophilia                                                        Imatinib with FLAG-Ida followed by matched unrelated allograft                                                 Relapsed with Imatinib resistance; started on Dasatinib but died 15 months later
  Lierman et al., Leukemia. 2009 May;23(5):845-51                Chronic eosinophilic leukemia blast crisis with Imatinib resistance                             Sorafenib 400 mg BID                                                                                           Hematologic response without molecular response for 3 months
  Zota et al., J Clin Oncol. 2008 Apr 20;26(12):2040-1           Chronic myelomonocytic leukemia                                                                 Imatinib 400 mg BID                                                                                            Resolution of eosinophilia without other hematologic response; progressed to extramedullary disease
  Florian et al., Leuk Res. 2006 Sep;30(9):1201-5                Systemic mastocytosis with chronic eosinophilic leukemia                                        Incomplete response to hydroxyurea, corticosteroids and interferon-alpha; started on imatinib 100 mg in 2002   Long-term response to low-dose Imatinib (50-100 mg) after inadequate responses to previous therapies
  Von Bubnoff et al., Leukemia. 2005 Feb;19(2):286-7             Chronic myeloproliferative disorder with eosinophilia                                           Imatinib 100-400 mg daily                                                                                      Hematologic and symptomatic response for 6 months; progression to myeloid blasts crisis and malignant pleural effusion
  Saflet et al., Genes Chromosomes Cancer 2004 May;40(1):44-50   Atypical chronic myeloid leukemia with t(4;22) leading to formation of BCR-PDGFRA fusion gene   Imatinib 100 mg daily                                                                                          Complete hematologic response at 7-month follow up

Our case highlights the importance of assessing for *PDGFRA* rearrangement in myeloid neoplasms with *de novo* or subsequently acquired eosinophilia. The identification of the *FIP1L1- PDGFRA* fusion gene is significant since imatinib has excellent efficacy at low doses (100-400 mg daily) in *FIP1L1-PDGFRA*-positive neoplasms \[[@B2],[@B5]\]. Of note, due to the 250-fold lower IC~50~ as compared to *BCR-ABL*, reports suggest that even once weekly doses of imatinib are adequate in the setting of *FIP1L1-PDGFRA*\[[@B3]\]. However, these responses are eventually lost due to emergence of an imatinib-resistant T614I mutation in the ATP-binding site of *PDGFRA*\[[@B9]\]. In our patient, the ability to induce a complete remission using imatinib at a time when the patient was unresponsive to chemotherapy induction permitted subsequent allogeneic SCT and an ensuing durable remission as of last follow up.

Conclusion
==========

We describe a case report of a patient who transformed from CMML to AML which was refractory to standard chemotherapy. Emergence of peripheral and bone marrow hypereosinophilia during this transformation led to suspicion of presence of *FIP1L1-PDGFRA* rearrangement, which was confirmed by FISH and RT-PCR. Treatment with imatinib led to a complete remission and permitted allogeneic SCT therapy.

Endnote
=======

The identification of new onset of eosinophilia in acute myeloid leukemia arising in a patient with chronic myelomonocytic leukemia might indicate acquisition of imatinib-responsive *FIP1L1-PDGFRA* rearrangement.
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